

A New Rearrangement in *Iboga* Alkaloids

by **Alberto Madinaveitia**, **Gabriel de la Fuente***, and **Antonio González**

Instituto de Productos Naturales y Agrobiología e Instituto Universitario de Bio-Organica,
CSIC-Universidad de La Laguna, Ctra a la Esperanza, 2, E-38206, La Laguna, Tenerife


The hydroxyindolenine **2**, upon treatment with Ac_2O in pyridine, rearranged into the bridged 16-spiro compound **3**. Compound **3** can be considered to be a synthon of the carbocation at C(16) of ibogaine (**7**) since the solvolysis of **3** in $\text{EtOH}/\text{H}_2\text{O}$ gave a mixture of the 16-ethoxy- and 16-hydroxyibogaine derivatives **5** and **6**, respectively.

Introduction. – The hydroxyindolenines and derivatives have proved to be versatile compounds in the chemistry of indole alkaloids. The treatment of iboga hydroxyindolenine alkaloids with methanolic hydrogen chloride [1] or sodium methoxide [2] gave the corresponding pseudoindoxyl, and the acetoxindolenines of the yohimbinoïd alkaloids were used in the synthesis of oxindole derivatives [3]. In a previous work [4], we described the isomerization at the OH-substituted C(7)¹ followed by decarboxylation at C(16), in basic media, of the voacangine hydroxyindolenine (**1**), the major autoxidation product of voacangine (**4**) [5], to give the hydroxyindolenine **2**. Now we report on the rearrangement of the hydroxyindolenine **2** into the spiro-bridged compound **3** and that of **3** to give the 16-ethoxy and 16-hydroxy derivatives **5** and **6**, respectively, of ibogaine (= 10-methoxyibogamine; **7**)¹.


Results and Discussion. – When the hydroxyindolenine **2** was treated at room temperature with Ac_2O in pyridine, the rearranged compound **3** was obtained as the sole reaction product. The ¹H- and ¹³C-NMR spectra (*Tables 1* and *2*) showed signals for the ethyl side chain ($\delta(\text{H})$ 0.96(*t*), 1.60(*m*), 1.93(*m*); $\delta(\text{C})$ 12.8(*q*), 28.9(*t*)), an aromatic MeO group ($\delta(\text{H})$ 3.86(*s*); $\delta(\text{C})$ 55.9(*q*)), and a secondary-acetate group ($\delta(\text{H})$ 2.04(*s*), 4.51(*s*); HMQC: $\delta(\text{C})$ 81.9(*d*); HMBC $\delta(\text{C})$ 169.3(*s*)). The presence of a secondary-acetate group in the molecule, together with a new C-signal (*s* at $\delta(\text{C})$ 62.4) in the ¹³C-NMR spectrum indicated that a rearrangement of the iboga skeleton had taken place. A broad signal at $\delta(\text{H})$ 7.73(*s*, 1 H, H–N(1)), together with the low-field C-signals, revealed the generation of the indole nucleus during the reaction, and permitted us to assign, among others, the signals of C(2), C(7), and C(8)¹ ($\delta(\text{C})$ 138.0(*s*), 109.6(*s*), and 130.8(*s*), resp.) [6].

Taking into account the chemical shifts, the C-resonances $\delta(\text{C})$ 50.9(*t*; HMQC: $\delta(\text{H})$ 2.61 and 3.17), 60.3(*t*; $\delta(\text{H})$ 3.12 and 2.66), and 62.4(*s*) were ascribed to C-atoms bound to an N-atom of **3**. In the ¹H,¹H-COSY, an *ABMX* system for CH_2CH_2 was evident at $\delta(\text{H})$ 2.76 and 2.73 (HMQC: $\delta(\text{C})$ 21.6(*t*) and 2.61 and 3.17 (HMQC: $\delta(\text{C})$ 50.9(*t*)). Moreover, the following long-range connectivities corresponding to one-proton signals


¹) Trivial numbering according to *Formulae*; for systematic names, see *Exper. Part*. H_R and H_S are short forms of H_{pro-R} and H_{pro-S}, respectively.




- 1 R¹ = β-OH, R² = COOCH₃
 2 R¹ = α-OH, R² = H
 8 R¹ = α-OAc, R² = H
 14 R¹ = β-OAc, R² = COOCH₃



- 4 R = COOCH₃
 5 R = OCH₂CH₃
 6 R = OH
 7 R = H
 13 R = OAc



3



3a

Table 1. ¹H,¹³C-HMQC and ¹H,¹³C-HMBC-NMR Data of 3^a)

	δ(H)	Correlated C-atom	
		HMQC	HMBC
H _R -C(3)	3.12 (<i>d</i> , <i>J</i> = 9.2)	60.3 (<i>t</i>)	C(15), C(16), C(17)
H _S -C(3)	2.66 (<i>dd</i> , <i>J</i> = 5.0, 9.2)	60.3 (<i>t</i>)	C(5), C(14), C(15)
H _R -C(5)	2.61 (<i>ddd</i> , <i>J</i> = 4.3, 10.1, 10.1)	50.9 (<i>t</i>)	C(3), C(7)
H _S -C(5)	3.17 (<i>ddd</i> , <i>J</i> = 3.7, 3.7, 10.3)	50.9 (<i>t</i>)	C(7), C(16)
H _R -C(6)	2.76 (<i>ddd</i> , <i>J</i> = 4.1, 14.0, 14.0)	21.6 (<i>t</i>)	C(2), C(5), C(7), C(8)
H _S -C(6)	2.73 (<i>ddd</i> , <i>J</i> = 3.7, 3.7, 14.0)	21.6 (<i>t</i>)	C(2), C(5), C(7), C(8)
H-C(9)	6.97 (<i>d</i> , <i>J</i> = 2.4)	100.6 (<i>d</i>)	C(7), C(10), C(11), C(13)
H-C(11)	6.80 (<i>dd</i> , <i>J</i> = 2.5, 8.7)	111.3 (<i>d</i>)	C(9), C(10), C(13)
H-C(12)	7.18 (<i>d</i> , <i>J</i> = 8.7)	111.0 (<i>d</i>)	C(8), C(10)
H-C(14)	2.47 (<i>ddd</i> , <i>J</i> = 4.2, 4.2, 8.4)	34.4 (<i>d</i>)	
H _R -C(15)	1.90 (<i>m</i>) ^b	30.5 (<i>t</i>)	C(3), C(19), C(20)
H _S -C(15)	1.58 (<i>m</i>) ^b	30.5 (<i>t</i>)	C(17), C(19), C(20), C(21)
H _R -C(17)	1.67 (<i>dd</i> , <i>J</i> = 4.6, 11.2)	35.1 (<i>t</i>)	C(2), C(14), C(15), C(16), C(21)
H _S -C(17)	2.25 (<i>d</i> , <i>J</i> = 11.0)	35.1 (<i>t</i>)	C(3), C(14), C(15), C(21)
Me-(18)	0.96 (<i>t</i> , <i>J</i> = 7.1)	12.8 (<i>q</i>)	C(19), C(20), C(21)
H _R -C(19)	1.93 (<i>m</i>) ^b	28.9 (<i>t</i>)	C(15), C(18), C(20), C(21)
H _S -C(19)	1.60 (<i>m</i>) ^b	28.9 (<i>t</i>)	C(15), C(18), C(20), C(21)
H-C(20)	1.62 (<i>m</i>) ^b	39.7 (<i>d</i>)	C(14), C(15), C(16), C(18), C(19), C(21)
H-C(21)	4.51 (<i>s</i>)	81.9 (<i>d</i>)	C(2), C(15), C(16), C(17), C(19), C(20), CO
MeO-C(10)	3.86 (<i>s</i>)	55.9 (<i>q</i>)	C(10)
Ac	2.04 (<i>s</i>)	21.6 (<i>q</i>)	CO
H-N(1)	7.73 (<i>br. s</i>)	-	C(2), C(7), C(8), C(13)

^a) Chemical shifts in ppm rel. to SiMe₄ (= 0); coupling constants *J* in Hz. The *Hanson* system for prochirality is used to identify the protons [7]. ^b) Overlapped signals.

Table 2. ^{13}C -NMR (125 MHz) Assignments for Compounds **3**–**7**^{a)}

	3	4	5	6	7
C(2)	138.0	137.7	138.3	138.4	142.9
C(3)	60.3	51.6	49.6	48.6	50.0
C(5)	50.9	53.2	52.8	53.3	54.2
C(6)	21.6	22.2	22.4	21.5	20.7
C(7)	109.6	110.1	108.9	108.5	109.1
C(8)	130.8	129.2	129.3	129.2	129.7
C(9)	100.6	100.8	100.9	100.7	100.3
C(10)	153.9	154.0	153.8	153.9	
C(11)	111.2	111.9	111.5	111.4	110.8
C(12)	111.0	111.2	110.8	111.1	110.6
C(13)	126.7	130.7	130.5		130.0
C(14)	34.4	27.4	27.4	27.7	26.5
C(15)	30.5	32.1	32.3	31.6	32.0
C(16)	62.4	55.2	79.8	74.8	42.0
C(17)	35.1	36.5	42.4	43.0	34.2
C(18)	12.8	11.7	11.7	11.7	11.9
C(19)	28.8	26.8	26.6	27.1	27.8
C(20)	39.7	39.1	33.8	34.3	41.5
C(21)	81.9	57.5	58.3	63.3	57.5
MeO–C(10)	55.9	56.0	56.0	55.9	56.0
MeOOC–C(16)	–	175.8	–	–	–
MeOOC–C(16)	–	52.6	–	–	–
MeCH ₂ O–(16)	–	–	15.8	–	–
Me ₃ CH ₂ O–(16)	–	–	58.9	–	–
Ac	169.3, 21.6	–	–	–	–

^{a)} Chemical shifts in ppm rel. to SiMe₄ (= 0); solvent CDCl₃.

were observed in the HMBC spectrum: $\delta(\text{H})$ 2.76 and 2.73 with C(2) and C(8), $\delta(\text{H})$ 3.17 with C(7) and 62.4 (s), $\delta(\text{H})$ 3.12 with $\delta(\text{C})$ 62.4 (s), and $\delta(\text{H})$ 2.66 with 50.9 (t). These findings were in accord with the partial structure **3a** for the rearranged product and allowed us to assign the H- and C-resonances for CH₂(3), CH₂(5), CH₂(6), and C(16) (Table 1). The remaining C- and H-signals in the NMR spectra and homo- and hetero-correlations observed in the 2D spectra were in agreement with the proposed structure for **3**. The ¹H,¹H-COSY showed scalar correlations between H_S–C(3) ($\delta(\text{H})$ 2.66) and H–C(14) ($\delta(\text{H})$ 2.47) which in turn gave a one-bond correlation with the methine resonance at $\delta(\text{C})$ 34.4, in the HMQC spectrum; H–C(14) was correlated to H_R–C(17) ($\delta(\text{H})$ 1.67, $\delta(\text{C})$ 35.1 (t)), H_S–C(15) ($\delta(\text{H})$ 1.58, $\delta(\text{C})$ 30.5 (t)), and H_R–C(15) ($\delta(\text{H})$ 1.90, $\delta(\text{C})$ 30.5 (t)); H_R–C(15) was correlated to H–C(20) ($\delta(\text{H})$ 1.62, $\delta(\text{C})$ 39.7 (d)), and H–C(20) to H_R–C(19) ($\delta(\text{H})$ 1.60, $\delta(\text{C})$ 28.9 (t)) and to H–C(21) ($\delta(\text{H})$ 4.51, $\delta(\text{C})$ 81.9 (d)). Additionally, three-bond connectivities were observed in the HMBC spectrum between H_R–C(3) and C(15) and C(17), between H_S–C(3) and C(15), and between both H_R–C(17) and H–C(21) and C(2). Furthermore, in the NOESY experiment, spatial correlations were detected between H–N(1) and the nonequivalent protons CH₂(17) as well as H–C(21). The cyclohexane ring must be in a chair conformation, possessing C(3) and C(19) in axial position, in view of the chemical shift of one of the nonequivalent protons CH₂(19) at $\delta(\text{H})$ 1.93 (H_R–C(19); deshielding effect of the lone electron pair of the N-atom) and the NOE observed for H_R–C(3) and CH₂(19). Since H–C(21) also showed an NOE with H_R–C(19), the secondary-acetate group is also in axial position. The small coupling constant between the equatorial protons H–C(21) and H–C(20) observed in the ¹H,¹H-COSY revealed that the cyclohexane ring is in a slightly distorted chair conformation, due to the axial position of C(3), N(4), and C(19). The position of the methylene protons was mainly deduced from the NOEs and the W couplings observed in the NOESY and ¹H-COSY, respectively (Table 3).

Treatment of **3** with EtOH/H₂O at room temperature yielded compounds **5** (C₂₂H₃₀N₂O₂) and **6** (C₂₀H₂₆N₂O₂) as the sole reaction products. The analysis of their


Table 3. *Scalar and Spatial Correlation of the Protons of 3¹*

	COSY	NOESY
H _R -C(3)	H _S -C(3), H _S -C(17)(W)	H _S -C(3), H-C(14), H _S -C(15), H _R -C(19), H _R -C(19), Me(18)
H _S -C(3)	H _R -C(3), H-C(14), H _R -C(15)(W)	H _R -C(3), H _R -C(5), H-C(14), H _R -C(17)
H _R -C(5)	H _S -C(5), H _R -C(6), H _S -C(6)	H _S -C(3), H _S -C(6), H _S -C(5), H _R -C(17)
H _S -C(5)	H _R -C(5), H _R -C(6), H _S -C(6)	H _R -C(5), H _R -C(6), H _S -C(6)
H _R -C(6)	H _R -C(5), H _S -C(5), H _S -C(6)	H _S -C(5), H _S -C(6)
H _S -C(6)	H _R -C(5), H _S -C(5), H _R -C(6)	H _R -C(5), H _S -C(5), H _R -C(6), H-C(9)
H-C(9)	H-C(11)	H _S -C(6), MeO-C(10)
H-C(11)	H-C(9), H-C(12)	H-C(12)
H-C(12)	H-C(11)	H-C(11), H-N(1)
H-C(14)	H _S -C(3), H _R -C(15), H _S -C(15), H _R -C(17), H _S -C(17) H-C(20)(W)	H _R -C(3), H _S -C(3), H _R -C(15), H _S -C(15), H _R -C(17), H _S -C(17)
H _R -C(15)	H-C(14), H-C(20), H _S -C(15)	H-C(14), H _S -C(15), H _S -C(17), H-C(20)
H _S -C(15)	H _R -C(15)	H _R -C(3), H-C(14), H _R -C(15), Me(18)
H _R -C(17)	H-C(14), H _S -C(17), H-C(21)(W)	H _S -C(3), H _R -C(5), H-C(14), H _S -C(17), H-N(1)
H _S -C(17)	H _R -C(3)(W), H _R -C(17)	H-C(14), H _R -C(15), H _R -C(17), H-C(20), H-N(1)
Me(18)	H _R -C(19), H _S -C(19)	H _R -C(3), H _S -C(15), H _R -C(19), H _S -C(19), H-C(20), H-C(21)
H _R -C(19)	MeC(18), H _S -C(19), H-C(20)	H _R -C(3), Me(18), H _S -C(19), H-C(20), H-C(21)
H _S -C(19)	Me(18), H _R -C(19), H-C(20)	H _R -C(3), Me(18), H _R -C(19), H-C(20), H-C(21)
H-C(20)	H-C(14)C(W), H _R -C(15), H _R -C(19), H _S -C(19), H-C(21)	H _S -C(17), H _R -C(19), H _S -C(19), H-C(21), Ac
H-C(21)	H _R -C(17)C(W), H-C(20)	Me(18), H _R -C(19), H-C(20), H-N(1)
MeO-C(10)	-	H-C(9), H-C(11)
Ac	-	H-C(20), H-C(21), H-N(1)
H-NC(1)	-	H-C(12), H _R -C(17), H _S -C(17), H-C(21)

¹H-NMR spectra and the comparison of their ¹³C-NMR data with those of voacangine (**4**) and ibogaine (**7**) [8] (*Table 2*) showed that **5** and **6** are 16-ethoxy- and 16-hydroxyibogaine, respectively.

The probable mechanism of formation of **3** from **2** and that of the solvolysis of **3** to give the ibogaine derivatives **5** and **6** is outlined in the *Scheme*. The delocalized cation **9**, produced by heterolysis of the non-isolated acetoxyindolenine **8** (see above), leads to the intermediate carbocation **10** by a 1,3-H shift. The intermediate **10** is in equilibrium with the rearranged carbocation **12** probably through the aziridinium transition state **11**, which is reached from both carbocations by the intramolecular attack of the lone electron pair of the N-atom. The anchimeric assistance by this lone electron pair also accounts for the easy solvolysis of **3** in EtOH/H₂O to afford **5** and **6** *via* the same transition state **11** and carbocation **10**. The fact that no products arising from solvent quenching of carbocation **12** were detected indicates that in the proposed equilibrium between **10** and **12**, the carbocation **10** is highly predominant. The sole formation of acetate **3** in the reaction of **2** with Ac₂O in pyridine could be explained by the facile

Scheme



solvolysis of the non-isolated acetate **13** (see above) and the irreversibility of the pathway from **12** to **3** (*Scheme*).

On the other hand, treatment of voacangine hydroxyindolenine (**1**) under stronger conditions, *i.e.*, refluxing in Ac₂O/Py, provided the acetoxyindolenine **14** (see above) [5] as the sole reaction product. A delocalized cation **15** is possibly formed too, but no hydride shift is feasible in this case (see *Scheme*). The existence of an ion-pair between the acetate ion and **15** could account for the fact that the reaction proceeds with retention of configuration at C(7).

The MS of compounds of compounds **3**, **5**, and **6** display peaks at *m/z* 309, 308, 293, 279, 266, and 239 which, in contrast, are unnoticed in the MS of voacangine (**4**) [9] and ibogaine (**7**) [10]. These facts suggest that the fragmentation pathways of **3**, **5** and **6** are alike and that the molecular ion of **5** and **6** undergoes a radical rearrangement resembling that of the carbocation **10** (*Scheme*), initiated by homolytic cleavage of the C(16)–OR bond.

Since compound **3** is a synthon of carbocation **10**, other ibogaine derivatives substituted at C(16) could be prepared from **3** by selection of the suitable solvent and nucleophile.

We thank the *Dirección General de Universidades e Investigación* (P-12/95) of the Gobierno Autónomo de Canarias and the *Spanish Dirección General de Enseñanza Superior* (PB97-1265) for financial support.

Experimental Part

1. *General*. Yields are given relative to reacted reagents. TLC: *Macherey-Nagel and Polygram-Alox-N* chromatoplates were used for anal. and prep. separations; detection by a UV lamp and with *Dragendorff* spray reagent. NMR: *Bruker-WP-200-SY* or *Bruker-AMX-500* spectrometers; in CDCl₃; δ values in ppm rel. to internal SiMe₄ (= 0 ppm); *J* values in Hz; DEPT, ¹H,¹H-COSY, HMQC, HMBC (*J* = 8 Hz), and NOESY (mixing time 500 ms) experiments with the pulse sequences given by *Bruker*, C-multiplicities by DEPT or HMQC data. Mass spectra (*m/z*; rel.%): *Micromass-Autospec* spectrometer at 70 eV.

2. (*1R,2S,4R,13bS*)-2-Ethyl-2,3,4,5,7,8-hexahydro-10-methoxy-13H-4,13b-methano-1H-azepino[1',2':1,2]pyrido[3,4-b]indol-1-ol Acetate (**3**). A mixture of **2** (4.6 mg), pyridine (0.5 ml), and Ac₂O (0.1 ml) was stirred at r.t. till disappearance of **2** (TLC, 8 d) and then evaporated. The residue was purified by prep. TLC (hexane/AcOEt 4:1): **3** (1.7 mg, 42%). ¹H-NMR (500 MHz) and ¹³C-NMR (125 MHz): *Tables 1* and *2*, resp. EI-MS: 368 (20, *M*⁺), 339 (4, [*M* – Et]⁺), 325 (30, [*M* – Ac]⁺), 309 (50, [*M* – AcO]⁺), 308(47, [*M* – AcOH]⁺), 293(5), 279(10), 266(54), 250(18), 239(100), 224(5), 149(6), 60(7). HR-EI-MS: 368.2186 (C₂₂H₂₈N₂O₃⁺; calc. 368.2099), 325.1903 (C₂₀H₂₅N₂O₃⁺; calc. 325.1903), 309.1999 (C₂₀H₂₅N₂O⁺; calc. 309.1966), 308.1926 (C₂₀H₂₄N₂O⁺; calc. 308.1888), 293.1578 (C₁₉H₂₁N₂O⁺; calc. 293.1655), 279.1545 (C₁₈H₁₉N₂O⁺; calc. 279.1497), 266.1427 (C₁₇H₁₈N₂O⁺; calc. 266.1419), 250.1205 (C₁₇H₁₆NO⁺; calc. 250.1231), 239.1200 (C₁₅H₁₅N₂O⁺; calc. 239.1184).

3. *Compounds 5 and 6 from 3*. A soln. of **3** (1.5 mg) in EtOH (3 ml) was left to stand at r.t. for three days and then evaporated. Anal. TLC revealed a mixture of two alkaloids of very different polarity in a ratio of *ca.* 1:1. The mixture was separated by prep. TLC (hexane/AcOEt 7:3): **5** (0.6 mg, 42%) and **6** (0.7 mg, 49%).

5-Ethoxy-12-methoxyibogamine (**5**). ¹H-NMR (500 MHz): 8.07 (br. s, H–N(1)); 7.21 (*d*, *J* = 8.6, H–C(12)); 6.94 (*d*, *J* = 2.4, H–C(9)); 6.84 (*dd*, *J* = 8.5, 2.4, H–C(11)); 3.87 (*s*, MeO–C(10)); 3.36 (*m*, H_R–C(5), H_A of MeCH₂–O–C(16)); 3.24 (*m*, H_S–C(5), H_S–C(6)); 3.15 (*m*, H_B of MeCH₂–O–C(16)); 3.00 (*s*, H–C(21)); 2.85 (*dt*, *J* = 8.4, 2.5, H_R–C(3)); 2.78 (*m*, H_R–C(6)); 2.72 (br. *d*, *J* = 8.4, H_S–C(3)); 1.99 (br. *m*, H–C(20)); 1.85 (*m*, H–C(14), CH₂(17), H_R–C(15)); 1.52 (*m*, CH₂(19)); 1.89 (*t*, *J* = 7.0, MeCH₂–O–C(16)); 1.12 (br. *m*, H_S–C(15)); 0.94 (*t*, *J* = 7.4, Me(18)). ¹³C-NMR (125 MHz): *Table 3*. EI-MS: 354 (25, *M*⁺), 326 (23), 325 (100, [*M* – Et]⁺), 309 (21), 308 (32, [*M* – EtOH]⁺), 279 (7), 266 (45), 250 (14), 239 (13), 224 (5), 174 (27), 163 (5), 136 (6), 122 (5). HR-EI-MS: 354.2336 (C₂₂H₃₀N₂O₃⁺; calc. 354.2307), 325.1936 (C₂₀H₂₅N₂O₃⁺; calc. 325.1916), 308.1795 (C₂₀H₂₄N₂O⁺; calc. 308.1888), 293.1642 (C₁₉H₂₁N₂O⁺; calc. 293.16553), 279.1474 (C₁₈H₁₉N₂O⁺; calc. 279.1497), 266.1491 (C₁₈H₂₀NO⁺; calc. 266.1544), 250.1225 (C₁₇H₁₆NO⁺; calc. 250.1231), 239.1164 (C₁₅H₁₅N₂O⁺; calc. 239.1184).

12-Methoxyibogamin-5-ol (**6**). $^1\text{H-NMR}$ (500 MHz) 1 : 8.35 (br. s, H–N(1)); 7.18 (*d*, $J=8.7$, H–C(12)); 6.89 (*d*, $J=2.4$, H–C(9)); 6.78 (*dd*, $J=8.7$, 2.4, H–C(11)); 3.83 (*s*, MeO–C(10)); 3.38 (*dq*, $J=11.5$, 2.0, $\text{H}_R\text{–C}(5)$); 3.27 (*ddd*, $J=14.0$, 14.0, 4.8, $\text{H}_S\text{–C}(6)$); 3.15 (*ddd*, $J=13.9$, 13.9, 3.9, $\text{H}_S\text{–C}(5)$); 2.88 (*dt*, $J=8.9$, 2.5, $\text{H}_R\text{–C}(3)$); 2.83 (*dt*, $J=8.9$, 1.5, $\text{H}_S\text{–C}(3)$); 2.71 (*d*, $J=1.6$ H–C(21)); 2.63 (*dq*, $J=14.5$, 2.5, $\text{H}_R\text{–C}(6)$); 2.13 (br. *m*, H–C(20)); 1.97 (*dt*, $J=14.1$, 2.9, $\text{H}_R\text{–C}(17)$); 1.91 (br. *s*, H–C(14)); 1.78 (*dt*, $J=13.8$, 2.2, $\text{H}_R\text{–C}(15)$); 1.75 (*d*, $J=14.5$, $\text{H}_S\text{–C}(17)$); 1.50 (*m*, $\text{CH}_2(19)$); 1.11 (*dm*, $J=9.7$, $\text{H}_S\text{–C}(15)$); 0.88 (*t*, $J=7.4$, Me(18)). NOESY (500 MHz) 1 : 2.88 ($\text{H}_R\text{–C}(3)$) \rightarrow 1.11 ($\text{H}_S\text{–C}(15)$); 2.83 ($\text{H}_S\text{–C}(3)$) \rightarrow 1.97 ($\text{H}_R\text{–C}(17)$) and 3.27 ($\text{H}_S\text{–C}(6)$); 3.15 ($\text{H}_S\text{–C}(5)$) \rightarrow 2.71 (H–C(21)). $^{13}\text{C-NMR}$ (125 MHz) *Table 2*. EI-MS: 326 (19, M^+), 309 (25, $[M - \text{OH}]^+$), 308 (96, $[M - \text{H}_2\text{O}]^+$), 293 (30), 279 (30), 267 (24), 266 (97), 265 (46), 250 (38), 239 (100), 225 (12), 210 (10), 204 (7), 192 (9), 173 (13), 160 (8), 154 (4), 136 (16), 122 (10), 84 (39), 59 (25). HR-EI-MS: 326.2006 ($\text{C}_{20}\text{H}_{26}\text{N}_2\text{O}_2^+$; calc. 326.1994), 309.1924 ($\text{C}_{20}\text{H}_{25}\text{N}_2\text{O}^+$; calc. 309.1966), 308.1896 ($\text{C}_{20}\text{H}_{24}\text{N}_2\text{O}^+$; calc. 308.1888), 293.1670 ($\text{C}_{19}\text{H}_{21}\text{N}_2\text{O}^+$; calc. 293.1655), 279.1536 ($\text{C}_{18}\text{H}_{19}\text{N}_2\text{O}^+$; calc. 279.1497), 266.1565 ($\text{C}_{18}\text{H}_{20}\text{NO}^+$; calc. 266.1544), 250.1268 ($\text{C}_{17}\text{H}_{16}\text{NO}^+$; calc. 250.1231), 239.1217 ($\text{C}_{15}\text{H}_{15}\text{N}_2\text{O}^+$; calc. 239.1184), 225.1173 ($\text{C}_{15}\text{H}_{15}\text{NO}^+$; calc. 225.1153), 136.1149 ($\text{C}_9\text{H}_{14}\text{N}^+$; calc. 136.1126).

4. *9 β -(Acetyloxy)-16,17-didehydro-9,17-dihydro-12-methoxyibogamine-18-carboxylic Acid Methyl Ester* (**14**). A soln. of **1** (3 mg) in pyridine (2 ml) and Ac_2O (0.1 ml) was refluxed for 2 h and then evaporated. TLC and $^1\text{H-NMR}$: **14** [5] *ca.* 2:1.

REFERENCES

- [1] B. Hwang, J. A. Weisbach, B. Douglas, R. Raffauf, M. P. Cava, K. Bessho, *J. Org. Chem.* **1969**, *34*, 412.
- [2] D. W. Thomas, K. Biemann, *Tetrahedron* **1968**, *24*, 4223.
- [3] N. Finch, C. W. Gemenden, I. Hsiu-Chu, W. I. Taylor, *J. Am. Chem. Soc.* **1963**, *85*, 1520.
- [4] A. Madinaveitia, G. de la Fuente, A. G. González, *Helv. Chim. Acta* **1998**, *81*, 1645.
- [5] A. Madinaveitia, M. Reina, G. de la Fuente, A. G. González, *J. Nat. Prod.* **1996**, *59*, 185.
- [6] R. Verpoorte, T. A. van Beek, R. L. M. Riegman, P. J. Hylands, N. G. Bisset, *Org. Magn. Reson.* **1984**, *22*, 328.
- [7] K. R. Hanson, *J. Am. Chem. Soc.* **1966**, *88*, 2731.
- [8] M. Damak, C. Poupat, A. Ahond, *Tetrahedron Lett.* **1976**, *39*, 3531.
- [9] K. Biemann, in 'Mass Spectrometry', Ed. McGraw-Hill, New York, 1962, p. 323.
- [10] K. Biemann, M. Friedmann-Spitteller, *J. Am. Chem. Soc.* **1961**, *83*, 4805.

Received October 5, 1998